- About ExoGenis
We unlock the power of biologics - without the burden of injections
- What we do
ExoGenis is building an injection-free, device-based delivery system for biologically active compounds, positioned between topical skincare and invasive procedures.
The platform is designed for controlled, repeatable use in clinical settings, enabling a new layer of treatment between major interventions.
our mission
To make precise biologic delivery accessible, predictable and scalable.
our vision
A future where biologic therapies are delivered locally and non-invasively.
.svg)
Biologic-
compatible
.svg)
Non-
injectable
Clinically
focused
.svg)
Scientifically
driven
- our team
Leadership and Scientific advisors
Irina Torres
CEO & Co-founder
EMBA (LBS) - MSc, Strategy, partnerships, IP, regulatory, fundraising
Dr. Elena Tsisanova
CMO, Co-founder
MPharm, MSc, PhD Pharmacology, medical devices, exosomes
Dr. Nina Tsisanova
Scientific advisor
Correction of age-related skin changes, treatment of vascular and pigment pathologies, and therapy for various manifestations of photo- and chronoaging
.svg)
Dr. John Ludlow
Scientific advisor
Tissue engineering, cell therapeutics, regenerative medicine, and GLP/GMP process and assay development for clinical-stage products
- our journey
Milestones
Our technology is validated through rigorous scientific partnerships with leading research institutions.
2025
2026
01
Company founded
ExoGenis established to develop a biologic-compatible microneedle delivery platform for fragile biologics.
02
Initial research & development
Core dissolvable microneedle architecture and coating approach developed.
03
Validated prototype
Technical validation of delivery performance, stability, and controlled depth completed in Denmark.
04
Clinical pilots
Launch with select partner clinics in Europe and the UK for real-world validation.
- Partnerships
Scientific collaborations
Our technology is validated through rigorous scientific partnerships with leading research institutions.
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
DTU — mechanical and release validation of microneedle system
Beyond Beta — accelerator support and early-stage validation
Join us in shaping the future
Whether you're a potential partner, investor, or simply curious about our technology, we'd love to hear from you.